|
Download
PDF
|
Pipeline Insight: Osteoporosis – Intermittent dosing drives market growth
The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment. Two pipeline products, Amgen’s Denosumab and Novartis’ Aclasta (zoledronate), have answered this demand with intermittent dosing schedules and consequently are expected to generate blockbuster revenues. This will rejuvenate the market which is otherwise stalling under
multiple patent expiries.
Osteoporosis is a systemic, degenerative skeletal condition characterized by low bone mass and micro architectural deterioration of bone, leading to reduced bone strength. This low bone mineral density makes patients prone to fractures which require considerable treatment resources if complications, including fatality, are to be avoided. The aging population and significant prevalence of osteoporosis creates a market that is varied and competitive. But, the imminent genericization of the gold-standard treatment Fosamax (alendronate) signals that the market is about to undergo dramatic change.
View
Table Of Contents >
|
